

VIRGINIA ACTS OF ASSEMBLY — CHAPTER

An Act to amend and reenact §§ 54.1-3303, 54.1-3401, 54.1-3408, 54.1-3410, 54.1-3411, 54.1-3422, 54.1-3426, 54.1-3435.2, 54.1-3443, 54.1-3446, and 54.1-3463 of the Code of Virginia, relating to the Drug Control Act.

[H 699]

Approved

Be it enacted by the General Assembly of Virginia:

1. That §§ 54.1-3303, 54.1-3401, 54.1-3408, 54.1-3410, 54.1-3411, 54.1-3422, 54.1-3426, 54.1-3435.2, 54.1-3443, 54.1-3446, and 54.1-3463 of the Code of Virginia are amended and reenacted as follows:

§ 54.1-3303. Prescriptions to be issued and drugs to be dispensed for medical or therapeutic purposes only.

A. A prescription for a controlled substance may be issued only by a practitioner of medicine, osteopathy, podiatry, dentistry or veterinary medicine who is authorized to prescribe controlled substances. The prescription shall be issued for a medicinal or therapeutic purpose and may be issued only to persons or animals with whom the practitioner has a bona fide ~~physician~~ *practitioner*-patient relationship.

For purposes of this section, a bona fide ~~physician~~ *practitioner*-patient-pharmacist relationship is one in which a ~~physician~~ *practitioner* prescribes, and a pharmacist dispenses, controlled substances in good faith to his patient for a medicinal or therapeutic purpose within the course of his professional practice. Any practitioner who prescribes any controlled substance with the knowledge that the controlled substance will be used otherwise than medicinally or for therapeutic purposes shall be subject to the criminal penalties provided in § 18.2-248 for violations of the provisions of law relating to the distribution or possession of controlled substances.

B. No prescription shall be filled which does not result from a bona fide ~~physician~~ *practitioner*-patient-pharmacist relationship. A prescription not issued in the usual course of treatment or for authorized research is not a valid prescription.

In order to determine whether a prescription which appears questionable to the pharmacist results from a bona fide ~~physician~~ *practitioner*-patient-pharmacist relationship, the pharmacist shall contact the prescribing ~~physician~~ *practitioner* or his agent and verify the identity of the patient and name and quantity of the drug prescribed. The person knowingly filling an invalid prescription shall be subject to the criminal penalties provided in § 18.2-248 for violations of the provisions of law relating to the sale, distribution or possession of controlled substances.

C. A pharmacist may dispense a controlled substance pursuant to a prescription of an out-of-state practitioner of medicine, osteopathy, podiatry, dentistry or veterinary medicine authorized to issue such prescription if the prescription complies with the requirements of this chapter and Chapter 34 (§ 54.1-3400 et seq.) of this title, known as the "Drug Control Act," *except that out-of-state prescriptions are not required to comply with the provisions of subsection A of § 32.1-87 and subsection C of § 54.1-3408 which establish a prescription blank format accommodating the Virginia Voluntary Formulary.*

D. A licensed nurse practitioner who is authorized to prescribe controlled substances pursuant to § 54.1-2957.01 may issue prescriptions for Schedule VI controlled substances and devices as set forth in Chapter 34 of this title in good faith to his patient for a medicinal or therapeutic purpose within the scope of his professional practice.

E. A licensed physician's assistant who is authorized to prescribe controlled substances pursuant to § 54.1-2952.1 may issue prescriptions for Schedule VI controlled substances and devices as set forth in Chapter 34 of this title in good faith to his patient for a medicinal or therapeutic purpose within the scope of his professional practice.

§ 54.1-3401. Definitions.

As used in this chapter, unless the context requires a different meaning:

"Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion or any other means, to the body of a patient or research subject by (i) a practitioner or by his authorized agent and under his direction, or (ii) the patient or research subject at the direction and in the presence of the practitioner.

"Advertisement" means all representations disseminated in any manner or by any means, other than by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the purchase of drugs or devices.

ENROLLED

HB699ER

57 "Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related
58 to testosterone, other than estrogens, progestins, and corticosteroids, that promotes muscle growth.

59 "Animal" means any nonhuman animate being endowed with the power of voluntary action.

60 "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer,
61 distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or
62 employee of the carrier or warehouseman.

63 "Board" means the Board of Pharmacy.

64 "Compound" means the taking of two or more ingredients and fabricating them into a single
65 preparation, usually referred to as a dosage form.

66 "Controlled substance" means a drug, substance or immediate precursor in Schedules I through VI of
67 this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms
68 are defined or used in Title 3.1 or Title 4.1.

69 "Cosmetic" means all articles intended to be rubbed, poured, sprinkled or sprayed on, introduced into
70 or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness or altering
71 the appearance, and articles intended for use as a component of any such articles except soap.

72 "DEA" means the Drug Enforcement Administration, United States Department of Justice, or its
73 successor agency.

74 "Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by
75 this chapter, whether or not there exists an agency relationship.

76 "Device" means instruments, apparatus, and contrivances, including their components, parts and
77 accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in
78 man or animals or to affect the structure or any function of the body of man or animals.

79 "Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the
80 lawful order of a practitioner, including the prescribing and administering, packaging, labeling or
81 compounding necessary to prepare the substance for that delivery.

82 "Dispenser" means a practitioner who dispenses.

83 "Distribute" means to deliver other than by administering or dispensing a controlled substance.

84 "Distributor" means a person who distributes.

85 "Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia
86 National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to
87 any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment or
88 prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect
89 the structure or any function of the body of man or animals; or (iv) articles or substances intended for
90 use as a component of any article specified in clause (i), (ii) or (iii). "Drug" does not include devices or
91 their components, parts or accessories.

92 "Hashish oil" means any oily extract containing one or more cannabinoids, but shall not include any
93 such extract with a tetrahydrocannabinol content of less than twelve percent by weight.

94 "Immediate precursor" means a substance which the Board of Pharmacy has found to be and by
95 regulation designates as being the principal compound commonly used or produced primarily for use,
96 and which is an immediate chemical intermediary used or likely to be used in the manufacture of a
97 controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

98 "Label" means a display of written, printed or graphic matter upon the immediate container of any
99 article. A requirement made by or under authority of this chapter that any word, statement or other
100 information appear on the label shall not be considered to be complied with unless such word, statement
101 or other information also appears on the outside container or wrapper, if any, of the retail package of
102 such article, or is easily legible through the outside container or wrapper.

103 "Labeling" means all labels and other written, printed or graphic matter on an article or any of its
104 containers or wrappers, or accompanying such article.

105 "Manufacture" means the production, preparation, propagation, compounding, conversion or
106 processing of any item regulated by this chapter, either directly or indirectly by extraction from
107 substances of natural origin, or independently by means of chemical synthesis, or by a combination of
108 extraction and chemical synthesis, and includes any packaging or repackaging of the substance or
109 labeling or relabeling of its container. This term does not include the preparing, compounding,
110 packaging or labeling of a controlled substance by a practitioner as an incident to his administering or
111 dispensing of a controlled substance or marijuana in the course of his professional practice, or by a
112 practitioner, or by his authorized agent under his supervision, for the purpose of, or as an incident to,
113 research, teaching, or chemical analysis and not for sale.

114 "Manufacturer" means every person who manufactures.

115 "Marijuana" means any part of a plant of the genus Cannabis whether growing or not, its seeds or
116 resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds,
117 or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids unless

such extract contains less than twelve percent of tetrahydrocannabinol by weight, or the mature stalks of such plant, fiber produced from such stalk, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture or preparation of such mature stalks, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination.

"Medical equipment supplier" means any person, as defined in § 1-13.19, engaged in the delivery to the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and needles, medicinal oxygen, Schedule VI controlled devices, and those Schedule VI controlled substances with no medicinal properties which are used for the operation and cleaning of medical equipment.

"Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative, or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in clause (i), but not including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain cocaine or ecgonine.

"New drug" means: (i) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling, except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use; or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions.

"Official compendium" means the official United States Pharmacopoeia National Formulary, official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

"Official written order" means an order written on a form provided for that purpose by the United States Drug Enforcement Administration, under any laws of the United States making provision therefor, if such order forms are authorized and required by federal law, and if no such order form is provided then on an official form provided for that purpose by the Board of Pharmacy.

"Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under Article 4 (§ 54.1-3437 et seq.) of this chapter, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.

"Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

"Original package" means the unbroken container or wrapping in which any drug or medicine is enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor for use in the delivery or display of such article.

"Person" means both the plural and singular, as the case demands, and includes individual, partnership, corporation, association, governmental agency, trust, or other institution or entity.

"Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

"Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01, licensed physician's assistant pursuant to § 54.1-2952.1, veterinarian, scientific investigator, or other person licensed, registered or otherwise permitted to distribute, dispense, prescribe and administer, or conduct research with respect to, a controlled substance in the course of professional practice or research in this Commonwealth.

"Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue a prescription.

"Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word of mouth, telephone, telegraph or other means of communication to a pharmacist by a duly licensed physician, dentist, veterinarian or other practitioner, authorized by law to prescribe and administer such drugs or medical supplies.

"Prescription drug" means any drug required by federal law or regulation to be dispensed only

179 pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503 (b) of
 180 the Federal Food, Drug, and Cosmetic Act.

181 "Production" or "produce" includes the manufacture, planting, cultivation, growing or harvesting of a
 182 controlled substance or marijuana.

183 "Proprietary medicine" means a completely compounded nonprescription drug in its unbroken,
 184 original package which does not contain any controlled substance or marijuana as defined in this chapter
 185 and is not in itself poisonous, and which is sold, offered, promoted or advertised directly to the general
 186 public by or under the authority of the manufacturer or primary distributor, under a trademark, trade
 187 name or other trade symbol privately owned, and the labeling of which conforms to the requirements of
 188 this chapter and applicable federal law. However, this definition shall not include a drug which is only
 189 advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a narcotic,
 190 a drug which may be dispensed only upon prescription or the label of which bears substantially the
 191 statement "Warning - may be habit-forming," or a drug intended for injection.

192 "Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any
 193 person, whether as individual, proprietor, agent, servant or employee.

194 "Warehouser" means any person, other than a wholesale distributor, engaged in the business of
 195 selling or otherwise distributing prescription drugs or devices to any person who is not the ultimate user
 196 or consumer. No person shall be subject to any state or local tax by reason of this definition.

197 "Wholesale distribution" means distribution of prescription drugs to persons other than consumers or
 198 patients, subject to the exceptions set forth in § 54.1-3401.1.

199 "Wholesale distributor" means any person engaged in wholesale distribution of prescription drugs
 200 including, but not limited to, manufacturers; repackers; own-label distributors; private-label distributors;
 201 jobbers; brokers; warehouses, including manufacturers' and distributors' warehouses, chain drug
 202 warehouses conducting wholesale distributions, and wholesale drug warehouses; independent wholesale
 203 drug traders; and retail pharmacies conducting wholesale distributions. No person shall be subject to any
 204 state or local tax as a wholesale merchant by reason of this definition.

205 The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) of this title and in this
 206 chapter shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus or
 207 glasses or lenses for the eyes.

208 The terms "pharmacist," "pharmacy" and "practice of pharmacy" as used in this chapter shall be
 209 defined as provided in Chapter 33 of this title unless the context requires a different meaning.

210 § 54.1-3408. Professional use by practitioners.

211 A. A practitioner of medicine, osteopathy, podiatry, or dentistry, a licensed nurse practitioner
 212 pursuant to § 54.1-2957.01 or a licensed physician's assistant pursuant to § 54.1-2952.1 shall only
 213 prescribe, dispense, or administer controlled substances in good faith for medicinal or therapeutic
 214 purposes within the course of his professional practice. The practitioner may prescribe, on a written
 215 prescription or on oral prescription as authorized by this chapter, and administer drugs and devices, or
 216 he may cause them to be administered by a nurse or intern under his direction and supervision, or a
 217 practitioner may prescribe and cause drugs and devices to be administered to patients in state-owned or
 218 state-operated hospitals or facilities licensed as hospitals by the Board of Health or psychiatric hospitals
 219 licensed by the State Mental Health, Mental Retardation and Substance Abuse Services Board by other
 220 persons who have been trained to properly administer drugs and who administer drugs only under the
 221 control and supervision of the practitioner or a pharmacist.

222 A practitioner may authorize registered nurses and licensed practical nurses to possess epinephrine
 223 for administration in treatment of emergency medical conditions pursuant to an oral or written order or
 224 standing protocol issued by a practitioner within the course of his professional practice.

225 A dentist may cause Schedule VI topical drugs to be administered under his direction and
 226 supervision by either a dental hygienist or by an authorized agent certified by the Board of Dentistry
 227 who has satisfactorily completed a training program for this purpose that is approved by the Board of
 228 Dentistry.

229 No written prescription order form shall include more than one prescription. This provision shall not
 230 apply, however, to the entry of any order on a patient's chart in any hospital or any long-term care
 231 facility, as defined in Board regulations, in Virginia or to a prescription ordered through the pharmacy
 232 operated by the Department of Corrections, the central pharmacy of the Department of Health, or the
 233 central outpatient pharmacy operated by the Department of Mental Health, Mental Retardation and
 234 Substance Abuse Services.

235 Such a prescription shall be written, dated, and signed by the person prescribing on the day when
 236 issued, and shall bear the full name and address of the patient for whom the drug is prescribed, and the
 237 full name, address, and registry number under the federal laws of the person prescribing, if he is
 238 required by those laws to be so registered.

239 This section shall not prevent the administration of drugs by a person who has satisfactorily

completed a training program for this purpose approved by the Board of Nursing and who administers such drugs in accordance with a physician's instructions pertaining to dosage, frequency, and manner of administration, when the drugs administered would be normally self-administered by (i) a resident of a facility licensed or certified by the State Mental Health, Mental Retardation and Substance Abuse Services Board; (ii) a resident of any adult care residence which is licensed by the Department of Social Services; (iii) a resident of the Virginia Rehabilitation Center for the Blind; (iv) a resident of a facility approved by the Board or Department of Youth and Family Services for the placement of children in need of services or delinquent or alleged delinquent youth; or (v) a program participant of an adult day care center licensed by the Department of Social Services.

This section shall not interfere with any ~~practitioner~~ *prescriber* issuing prescriptions in compliance with the provisions of this section to a Board agent for use pursuant to subsection G of § 18.2-258.1. Such prescriptions issued by such ~~practitioner~~ *prescriber* shall be deemed to be valid prescriptions. This section shall not prohibit a ~~practitioner~~ *prescriber* from using preprinted prescriptions for drugs classified in Schedule VI if all requirements concerning dates, signatures, and other information specified above are otherwise fulfilled.

B. The written prescription referred to in subsection A of this section shall be written with ink or individually typed and each prescription shall be manually signed by the ~~practitioner~~ *prescriber*. The prescription may be prepared by an agent for his signature. The prescription shall contain the name, address, telephone number, and federal controlled substances registration number assigned to the prescriber. The prescriber's information shall be either preprinted upon the prescription blank, typewritten, rubber stamped, or printed by hand.

C. Pursuant to § 32.1-87, the prescription form shall include two boxes, one labelled "Voluntary Formulary Permitted" and the other labelled "Dispense As Written." A prescriber may indicate his permission for the dispensing of a drug product included in the Formulary upon signing a prescription form and marking the box labelled "Voluntary Formulary Permitted." A Voluntary Formulary product shall be dispensed if the prescriber fails to indicate his preference. If no Voluntary Formulary product is immediately available, or if the patient objects to the dispensing of a generic drug, the pharmacist may dispense a brand name drug. On and after July 1, 1993, printed prescription forms shall provide:

- ☐ Dispense As Written
- ☐ Voluntary Formulary Permitted

.....

Signature of prescriber

If neither box is marked, a Voluntary Formulary product must be dispensed."

D. ~~Practitioners'~~ *Prescribers'* orders, whether written as chart orders or prescriptions, for Schedules II, III, IV and V controlled drugs to be administered to (i) patients or residents of long-term care facilities served by a Virginia pharmacy from a remote location or (ii) patients receiving parenteral, intravenous, intramuscular, subcutaneous or intraspinal infusion therapy and served by a home infusion pharmacy from a remote location, may be transmitted to that remote pharmacy by an electronic communications device over telephone lines which send the exact image to the receiver in hard-copy form, and such facsimile copy shall be treated as a valid, original prescription order.

§ 54.1-3410. When pharmacist may sell and dispense drugs.

A. A pharmacist, acting in good faith, may sell and dispense drugs and devices to any person pursuant to a prescription of a ~~practitioner~~ *prescriber* as follows:

1. A drug listed in Schedule II shall be dispensed only upon receipt of a written prescription that is properly executed, dated and signed by the person prescribing on the day when issued and bearing the full name and address of the patient for whom, or of the owner of the animal for which, the drug is dispensed, and the full name, address, and registry number under the federal laws of the person prescribing, if he is required by those laws to be so registered. If the prescription is for an animal, it shall state the species of animal for which the drug is prescribed;

2. In emergency situations, Schedule II drugs may be dispensed pursuant to an oral prescription in accordance with the Board's regulations;

3. Whenever a pharmacist dispenses any drug listed within Schedule II on a prescription issued by a ~~practitioner~~ *prescriber*, he shall affix to the container in which such drug is dispensed, a label showing the prescription serial number or name of the drug; the date of initial filling; his name and address, or the name and address of the pharmacy; the name of the patient or, if the patient is an animal, the name of the owner of the animal and the species of the animal; the name of the ~~practitioner~~ *prescriber* by whom the prescription was written; and such directions as may be stated on the prescription.

B. A drug controlled by Schedules III through VI or a device controlled by Schedule VI shall be dispensed upon receipt of a written or oral prescription as follows:

1. If the prescription is written, it shall be properly executed, dated and signed by the person prescribing on the day when issued and bear the full name and address of the patient for whom, or of

the owner of the animal for which, the drug is dispensed, and the full name and address of the person prescribing. If the prescription is for an animal, it shall state the species of animal for which the drug is prescribed.

2. If the prescription is oral, the ~~practitioner~~ *prescriber* shall furnish the pharmacist with the same information as is required by law in the case of a written prescription for drugs and devices, except for the signature of the prescriber.

A pharmacist who dispenses a Schedule III through VI drug or device shall label the drug or device as required in subdivision A 3 of this section.

C. A drug controlled by Schedule VI may be refilled without authorization from the prescriber if, after reasonable effort has been made to contact him, the pharmacist ascertains that he is not available and the patient's health would be in imminent danger without the benefits of the drug. The refill shall be made in compliance with the provisions of § 54.1-3411.

If the written or oral prescription is for a Schedule VI drug or device and does not contain the address or registry number of the prescriber, or the address of the patient, the pharmacist need not reduce such information to writing if such information is readily retrievable within the pharmacy.

D. Pursuant to authorization of the prescriber, an agent of the prescriber on his behalf may orally transmit a prescription for a drug classified in Schedules III through VI if, in such cases, the written record of the prescription required by this subsection specifies the full name of the agent of the prescriber transmitting the prescription.

§ 54.1-3411. When prescriptions may be refilled.

Prescriptions may be refilled as follows:

1. A prescription for a drug in Schedule II may not be refilled.

2. A prescription for a drug in Schedules III or IV may not be filled or refilled more than six months after the date on which such prescription was issued and no such prescription may be authorized to be refilled, nor be refilled, more than five times, except that any prescription for such a drug after six months from the date of issue, or after being refilled five times, may be renewed by the ~~practitioner~~ *prescriber* issuing it either in writing, or orally, if promptly reduced to writing and filed by the pharmacist filling it.

3. A prescription in Schedule VI may not be refilled, unless authorized by the ~~practitioner~~ *prescriber* either on the face of the original prescription or orally by the ~~practitioner~~ *prescriber* except as provided in subdivision 4 of this section. Oral instructions shall be reduced promptly to writing by the pharmacist and filed on or with the original prescription.

4. A prescription for a drug controlled by Schedule VI may be refilled without authorization from the prescriber if: reasonable effort has been made to communicate with the prescriber, and the pharmacist has determined that he is not available and the patient's health would be in imminent danger without the benefits of the drug. The pharmacist shall inform the patient of the prescriber's unavailability and that the refill is being made without his authorization. The pharmacist shall promptly inform the prescriber of such refill. The date and quantity of the refill, the prescriber's unavailability and the rationale for the refill shall be noted on the reverse side of the prescription.

§ 54.1-3422. Controlled substances registration certificate required in addition to other requirements; exemptions.

A. Every person who manufactures, distributes or dispenses any substance which is controlled in Schedules I through V or who proposes to engage in the manufacture, distribution or dispensing of any such controlled substance except licensed pharmacies and those persons who are licensed pharmacists shall obtain annually a controlled substances registration certificate issued by the Board. This registration shall be in addition to other licensing or permitting requirements enumerated in this chapter or otherwise required by law.

B. Registration under this section and under all other applicable registration requirements shall entitle the registrant to possess, manufacture, distribute, dispense, or conduct research with those substances to the extent authorized by this registration and in conformity with the other provisions of this chapter.

C. The following persons need not register and may possess controlled substances in Schedules I through V:

1. An agent or employee of any holder of a controlled substance registration certificate if he is acting in the usual course of his business or employment;

2. A common or contract carrier or warehouseman, or his employee, whose possession is in the usual course of business or employment; or

3. An ultimate user or a person in possession of any controlled substance pursuant to a lawful order of a ~~practitioner~~ *prescriber* or in lawful possession of a Schedule V substance.

D. A separate registration is required at each principal place of business or professional practice where the applicant manufactures, distributes, or dispenses controlled substances.

§ 54.1-3426. Regulations for special packaging.

A. The Board shall adopt standards for special packaging consistent with those promulgated pursuant to the federal Poison Prevention Packaging Act of 1970. The Board may exempt any drug from the requirements of special packaging and shall exempt any drug exempted pursuant to the Poison Prevention Packaging Act of 1970.

B. A ~~practitioner~~ *prescriber* or a purchaser may direct that a drug, which is subject to being dispensed in special packaging, be dispensed in other than special packaging.

§ 54.1-3435.2. Permit to act as medical equipment supplier; storage; limitation; regulations.

A. Unless otherwise authorized by this chapter or Chapter 33 (§ 54.1-3300 et seq.) of this title, it shall be unlawful for any person to act as a medical equipment supplier, as defined in § 54.1-3401, in this Commonwealth without a valid unrevoked permit issued by the Board. The applicant for a permit to act as a medical equipment supplier in this Commonwealth shall apply to the Board for a permit, using such form as the Board may furnish; renew such permit, if granted, annually on or before January 1 of each year; and remit a fee as determined by the Board.

B. Prescription drugs received, stored, and distributed by authority of this section shall be limited to those Schedule VI controlled substances with no medicinal properties which are used for the operation and cleaning of medical equipment.

C. Distribution of any Schedule VI drug or device or of any hypodermic needle or syringe, or medicinal oxygen by authority of this section is limited to delivery to the ultimate user upon lawful order by a ~~practitioner~~ *prescriber* authorized to prescribe such drugs and devices.

D. The Board may promulgate such regulations relating to the storage, handling, and distribution of prescription drugs, devices and controlled paraphernalia by medical equipment suppliers as it deems necessary to implement this section, to prevent diversion of prescription drugs and devices and controlled paraphernalia, and to protect the public.

§ 54.1-3443. Board to administer article.

A. The Board shall administer this article and may add substances to or ~~delete~~ *deschedule* or reschedule all substances enumerated in the schedules in this article pursuant to the procedures of the Administrative Process Act (§ 9-6.14:1 et seq.). In making a determination regarding a substance, the Board shall consider the following:

1. The actual or relative potential for abuse;
2. The scientific evidence of its pharmacological effect, if known;
3. The state of current scientific knowledge regarding the substance;
4. The history and current pattern of abuse;
5. The scope, duration, and significance of abuse;
6. The risk to the public health;
7. The potential of the substance to produce psychic or physical dependence; and
8. Whether the substance is an immediate precursor of a substance already controlled under this article.

B. After considering the factors enumerated in subsection A, the Board shall make findings and issue a regulation controlling the substance if it finds the substance has a potential for abuse.

C. If the Board designates a substance as an immediate precursor, substances which are precursors of the controlled precursor shall not be subject to control solely because they are precursors of the controlled precursor.

D. If any substance is designated, rescheduled, or ~~deleted~~ *descheduled* as a controlled substance under federal law and notice of such action is given to the Board, the Board may similarly control the substance under this chapter after the expiration of 120 days from publication in the Federal Register of the final order designating a substance as a controlled substance or rescheduling or deleting a substance without following the provisions specified in subsections A and B of this section.

E. Authority to control under this section does not extend to distilled spirits, wine, malt beverages, or tobacco as those terms are defined or used in Title 4.1.

F. The Board shall exempt any nonnarcotic substance from a schedule if such substance may, under the provisions of the federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.) or state law, be lawfully sold over the counter without a prescription.

§ 54.1-3446. Schedule I.

The controlled substances listed in this section are included in Schedule I:

1. Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

Acetylmethadol;

Allylprodine;

Alphamethylfentanyl;

Alphacetylmethadol (except levo-alpha-cetylmethadol, also known as levo-alpha-acetylmethadol,

423 levomethadyl acetate, or LAAM);

424 Alphameprodine;

425 Alphamethadol;

426 Benzethidine;

427 Betacetylmethadol;

428 Betameprodine;

429 Betamethadol;

430 Betaprodine;

431 Clonitazene;

432 Dextromoramide;

433 Diampromide;

434 Diethylthiambutene;

435 Difenoxin;

436 Dimenoxadol;

437 Dimepheptanol;

438 Dimethylthiambutene;

439 Dioxaphetylbutyrate;

440 Dipipanone;

441 Ethylmethylthiambutene;

442 Etonitazene;

443 Etoxidine;

444 Furethidine;

445 Hydroxypethidine;

446 Ketobemidone;

447 Levomoramide;

448 Levophenacymorphan;

449 Morpheridine;

450 Noracymethadol;

451 Norlevorphanol;

452 Normethadone;

453 Norpipanone;

454 Phenadoxone;

455 Phenampromide;

456 Phenomorphan;

457 Phenoperidine;

458 Piritramide;

459 Proheptazine;

460 Properidine;

461 Propiram;

462 Racemoramide;

463 Trimeperidine.

464 2. Any of the following opium derivatives, their salts, isomers and salts of isomers, unless
465 specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible
466 within the specific chemical designation:

467 Acetorphine;

468 Acetyldihydrocodeine;

469 Benzylmorphine;

470 Codeine methylbromide;

471 Codeine-N-Oxide;

472 Cyprenorphine;

473 Desomorphine;

474 Dihydromorphine;

475 Drotebanol;

476 Etorphine;

477 Heroin;

478 Hydromorphanol;

479 Methyl-desorphine;

480 Methyl-dihydromorphine;

481 Morphine methylbromide;

482 Morphine methylsulfonate;

483 Morphine-N-Oxide;

484 Myrophine;
 485 Nicocodeine;
 486 Nicomorphine;
 487 Normorphine;
 488 Phoclodine;
 489 Thebacon.
 490 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
 491 or preparation, which contains any quantity of the following hallucinogenic substances, or which
 492 contains any of its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers,
 493 and salts of isomers is possible within the specific chemical designation (for purposes of this subdivision
 494 only, the term "isomer" includes the optical, position, and geometric isomers):
 495 *Alpha-ethyltryptamine (some trade or other names: Monase; a-ethyl-1H-indole-3-ethanamine;*
 496 *3-[2-aminobutyl] indole; a-ET; AET);*
 497 *4-Bromo-2,5-dimethoxyphenethylamine (some trade or other names:*
 498 *2-[4-bromo-2,5-dimethoxyphenyl]-1-aminoethane; alpha-desmethyl DOB; 2C-B; Nexus);*
 499 3,4-methylenedioxy amphetamine;
 500 5-methoxy-3,4-methylenedioxy amphetamine;
 501 3,4,5-trimethoxy amphetamine;
 502 Bufotenine;
 503 Diethyltryptamine;
 504 Dimethyltryptamine;
 505 4-methyl-2,5-dimethoxyamphetamine;
 506 2,5-dimethoxy-4-ethylamphetamine (DOET);
 507 Ibogaine;
 508 Lysergic acid diethylamide;
 509 Mescaline;
 510 Parahexyl (some trade or other names: 3-Hexyl-1-hydroxy-7, 8, 9, 10-tetrahydro-6, 6,
 511 9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl);
 512 Peyote;
 513 N-ethyl-3-piperidyl benzilate;
 514 N-methyl-3-piperidyl benzilate;
 515 Psilocybin;
 516 Psilocyn;
 517 Tetrahydrocannabinols, except as present in marijuana and dronabinol in sesame oil and encapsulated
 518 in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug Administration;
 519 Hashish oil (some trade or other names: hash oil; liquid marijuana; liquid hashish);
 520 2,5-dimethoxyamphetamine (some trade or other names: 2,5-dimethoxy-a-methylphenethylamine;
 521 2,5-DMA);
 522 4-bromo-2,5-dimethoxyamphetamine (some trade or other names:
 523 4-bromo-2,5-dimethoxy-a-methylphenethylamine; 4-bromo-2,5-DMA);
 524 4-methoxyamphetamine (some trade or other names: 4-methoxy-a-methylphenethylamine;
 525 paramethoxyamphetamine; PMA);
 526 N-ethyl analog of phencyclidine;
 527 Pyrrolidine analog of phencyclidine;
 528 Thiophene analog of phencyclidine.
 529 4. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture
 530 or preparation which contains any quantity of the following substances having a depressant effect on the
 531 central nervous system, including its salts, isomers and salts of isomers whenever the existence of such
 532 salts, isomers and salts of isomers is possible within the specific chemical designation:
 533 Mecloqualone;
 534 Methaqualone.
 535 5. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture
 536 or preparation which contains any quantity of the following substances having a stimulant effect on the
 537 central nervous system, including its salts, isomers and salts of isomers:
 538 *Aminorex (some trade or other names; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,*
 539 *5-dihydro-5-phenyl-2-oxazolamine);*
 540 Fenethylamine;
 541 Ethylamphetamine;
 542 Cathinone (some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone,
 543 2-aminopropiophenone, and norephedrone);
 544 Methcathinone (some other names: 2-(methylanino)-propiofenone; alpha-(methylanino)

545 propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-methylaminopropiophenone;
 546 monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR
 547 1432).

548 6. Any material, compound, mixture or preparation containing any quantity of the following
 549 substances:

550 3-methylfentanyl-(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide), its optical and
 551 geometric isomers, salts, and salts of isomers;

552 3,4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts
 553 and salts of isomers;

554 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts and salts of isomers;

555 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts and salts of
 556 isomers;

557 N-[1-(1-methyl-2-phenyl)ethyl-4-piperidyl]-N-phenylacetamide (acetyl-alpha-methylfentanyl), its
 558 optical isomers, salts and salts of isomers;

559 N-[1-(1-methyl-2-2-thienyl)ethyl-4-piperidyl]-N-phenylpropanamide (alpha-methylthiofentanyl), its
 560 optical isomers, salts and salts of isomers;

561 N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of
 562 isomers;

563 N-[1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]-N-phenylpropanamide (beta-hydroxyfentanyl), its optical
 564 isomers, salts and salts of isomers;

565 N-[3-methyl-1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]-N-phenylpropanamide
 566 (beta-hydroxy-3-methylfentanyl), its optical and geometric isomers, salts and salts of isomers;

567 N-[3-methyl-1-(2-2-thienyl)ethyl-4-piperidyl]-N-phenylpropanamide (3-methylthiofentanyl), its optical
 568 and geometric isomers, salts and salts of isomers;

569 N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide(thenylfentanyl), its optical isomers, salts
 570 and salts of isomers;

571 N-[1-(2-2-thienyl)ethyl-4-piperidyl]-N-phenylpropanimide(thiofentanyl), its optical isomers, salts and
 572 salts of isomers.

573 § 54.1-3463. Exemption of drugs dispensed by filling or refilling prescription.

574 A. Any drug dispensed by filling or refilling a written or oral prescription of a practitioner licensed
 575 by law to administer such drug prescriber shall be exempt from the requirements of § 54.1-3462 except
 576 subdivisions 1, 9, and 10, and the packaging requirements of subdivision 7, if the drug bears a label
 577 containing the name and address of the dispenser, the serial number and date of the prescription or of its
 578 filling, the name of the prescriber and the name of the patient, and the directions for use and cautionary
 579 statements, if any, contained in such prescription.

580 B. This section shall not be construed to relieve any person from any requirement prescribed by or
 581 under authority of law with respect to drugs now included or which may hereafter be included within
 582 the classifications of narcotic drugs or marijuana as defined in the applicable federal and state laws
 583 relating to narcotic drugs and marijuana.